Trastuzumab and Chemotherapy May Be Appropriate for Small, Node-Negative, HER2-Positive Breast Cancer

被引：1
|
作者：
Morris, Patrick G. [1 ]
McArthur, Heather L. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Med, Breast Canc Med Serv, New York, NY 10065 USA
来源：
ONCOLOGIST | 2012年 / 17卷 / 10期
关键词：
D O I：
10.1634/theoncologist.2012-0318
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E33 / E33
页数：1
相关论文
共 50 条
  • [21] Benefit of adjuvant chemotherapy and trastuzumab in patients with HER2-positive, node-negative breast tumors ≤ 10 mm: a nationwide study
    Hassing, Christina M. S.
    Mejdahl, Mathias Kvist
    Laenkholm, Anne-Vibeke
    Kroman, Niels
    Knoop, Ann Soegaard
    Tvedskov, Tove Holst Filtenborg
    BREAST CANCER RESEARCH AND TREATMENT, 2022, 196 (01) : 197 - 206
  • [22] Benefit of adjuvant chemotherapy and trastuzumab in patients with HER2-positive, node-negative breast tumors ≤ 10 mm: a nationwide study
    Christina M. S. Hassing
    Mathias Kvist Mejdahl
    Anne-Vibeke Lænkholm
    Niels Kroman
    Ann Søegaard Knoop
    Tove Holst Filtenborg Tvedskov
    Breast Cancer Research and Treatment, 2022, 196 : 197 - 206
  • [23] The Effect of Adjuvant Treatment in Small Node-negative HER2-positive Breast Cancer: Which Subgroup Will Benefit?
    Lin, Haiping
    Zheng, Hongjuan
    Ge, Chenyang
    Wang, Qinghua
    Tang, Wanfen
    Zhang, Xia
    Zhou, Shishi
    Jin, Xiayun
    Xu, Xifeng
    Du, Jinlin
    Fu, Jianfei
    CLINICAL BREAST CANCER, 2020, 20 (06) : 503 - 510
  • [24] Small Tumor Size and Node-Negative HER2-Positive Breast Cancer: A Step Forward for a Better Treatment?
    Crivellari, Diana
    Molino, Annamaria
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (16) : E257 - E257
  • [25] Small HER2-positive, node-negative breast cancer: who should receive systemic adjuvant treatment?
    Joerger, M.
    Thuerlimann, B.
    Huober, J.
    ANNALS OF ONCOLOGY, 2011, 22 (01) : 17 - 23
  • [26] Cost-effectiveness of adjuvant paclitaxel and trastuzumab for early-stage node-negative, HER2-positive breast cancer
    Hajjar, Ali
    Ergun, Mehmet A.
    Alagoz, Oguzhan
    Rampurwala, Murtuza
    PLOS ONE, 2019, 14 (06):
  • [27] Clinical Significance of HER2-Positive and Triple-Negative Status in Small (≤ 1 cm) Node-Negative Breast Cancer
    Gorshein, Elan
    Klein, Paula
    Boolbol, Susan K.
    Shao, Theresa
    CLINICAL BREAST CANCER, 2014, 14 (05) : 309 - 314
  • [28] Treatment of Lymph Node-Negative, Early-Stage HER2-Positive Breast Cancer
    Oguz, Arzu
    Keskin, Gul Sema
    Colak, Dilsen
    Altundag, Ozden
    Akcali, Zafer
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (06) : 639 - +
  • [29] Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
    Piccart-Gebhart, MJ
    Procter, M
    Leyland-Jones, B
    Goldhirsch, A
    Untch, M
    Smith, I
    Gianni, L
    Baselga, J
    Bell, R
    Jackisch, C
    Cameron, D
    Dowsett, M
    Barrios, CH
    Steger, G
    Huang, CS
    Andersson, M
    Inbar, M
    Lichinitser, M
    Láng, I
    Nitz, U
    Iwata, H
    Thomssen, C
    Lohrisch, C
    Suter, TM
    Ruschoff, J
    Süto, T
    Greatorex, V
    Ward, C
    Straehle, C
    McFadden, E
    Dolci, MS
    Gelber, RD
    NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (16): : 1659 - 1672
  • [30] Adjuvant Trastuzumab Reduces Locoregional Recurrence in Women who Undergo Breast Conservation Therapy for Node-Negative HER2-Positive Breast Cancer
    Kiess, A. P.
    McArthur, H. L.
    Mahoney, K.
    Patil, S.
    Morris, P. G.
    Ho, A.
    Hudis, C. A.
    McCormick, B.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 78 (03): : S98 - S98
12345